Document:

Cytomedix, Inc.

209 Perry Parkway, Suite 7

Gaithersburg, MD 20877-2143

Re:        Cytomedix, Inc.

 

Ladies and Gentlemen:

 

The undersigned is the
holder and a beneficial owner (within the meaning of Rule 13d-3 under the Securities Exchange Act of 1934, as amended) of certain
shares of Common Stock, $.001 par value per share, outstanding on the date hereof (the “Securities”), listed
on the attached Exhibit A, of Cytomedix, Inc., a Delaware corporation (the “Company”). The undersigned
is receiving the Securities pursuant to the terms of (A) that Exchange and Purchase Agreement, by and among the Company, Aldagen,
Inc. (“Aldagen”), Aldagen Holdings, LLC (“Aldagen Holdings”) and the other named parties
thereto dated of even date herewith (the “Exchange Agreement”), and (B) that Subscription Agreement between
the undersigned and the Company dated of even date herewith (together, the “Cytomedix-Aldagen Transaction”).
The undersigned understands that execution and delivery of this Letter Agreement is required pursuant to the Exchange Agreement.

 

In order to induce the
Company to enter into the Cytomedix-Aldagen Transaction, the undersigned agrees, for the benefit of the Company, not to, without
the prior written consent of the Company: (1) offer, sell, contract to sell, sell any option or contract to purchase, purchase
any option or contract to sell, pledge, hypothecate, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, the Securities; or (2) enter into any swap or other arrangement that transfers to another, in whole
or in part, any of the economic consequences of ownership of the Securities, whether any such transaction described in clause (1)
or (2) above is to be settled by delivery of the Securities, in cash or otherwise, (A) with respect to [_] shares ([_]%) from the
date hereof until August 8, 2012, (B) with respect to [_] shares ([_]%) from the date hereof until the first anniversary of the
date hereof (the “Lock-Up Period”). Nothing contained herein shall restrict or prohibit the following:

 

		1.	the exercise of an option granted prior to the date hereof under any benefit plan of the Company
or the exercise of options or warrants, provided that the underlying shares of Common Stock shall be subject to the restrictions
of this letter agreement;

 

		2.	the transfer of any shares of Common Stock as a bona fide gift or for no consideration and any
transfers by will or intestate, provided that in each such case, each recipient of such shares agrees in writing to be subject
to the restrictions of this letter agreement;

 

		3.	the transfer to any trust, partnership or limited liability company for the direct or indirect
benefit of the undersigned and/or the immediate family of the undersigned for estate planning purposes, provided that (i) the trustee
of the trust, partnership or the limited liability company, as the case may be, agrees in writing to be subject to the restrictions
of this letter agreement and (ii) any such transfer shall not involve a disposition for value;

 

    	 

    	 

    

 

	Page 2

 

		4.	the transfer to an affiliate (as that term is defined in Rule 405 under the Securities Act of 1933,
as amended) of the undersigned, provided that such affiliate agrees in writing to be subject to the restrictions of this letter
agreement; and

 

		5.	if the undersigned is a corporation, partnership, limited liability company or other business entity,
the transfer to any shareholders, partners or members of, or owners of a similar equity interest in, the undersigned, as the case
may be, provided that (i) in any such case, the transferee agrees in writing to be subject to the restrictions of this letter agreement
and (ii) any such transfer shall not involve a disposition for value,

 

provided that no filing under
Section 16(a) of the Securities Exchange Act of 1934, as amended, shall be required or shall be voluntarily made in connection
with subsequent sales of Common Stock or other securities acquired in transfers or transactions specified in clauses (3) and (4)
above (other than a filing on a Form 5, Schedule 13D or Schedule 13G (or 13D/A or 13G/A), and other than such filings required
to be made after the restrictions contained in this letter agreement are no longer in effect).

 

The undersigned hereby
represents and warrants that the undersigned has full power and authority to enter into this Letter Agreement. This Letter Agreement
shall be binding on the undersigned and his, her or its respective successors, heirs, personal representatives and assigns. The
undersigned agrees and consents to the entry of stop transfer instructions with the Company’s transfer agent against the
transfer of the Securities or securities convertible into or exchangeable or exercisable for the Securities, held by the undersigned
except in compliance with this agreement.

 

This Letter Agreement shall
be governed by, and construed in accordance with, the laws of the State of Delaware.

 

Notwithstanding anything
herein to the contrary, this Letter Agreement shall automatically terminate and be of no further force or effect, and the undersigned
shall be released from all obligations under this Letter Agreement, if the Cytomedix-Aldagen Transaction is not consummated on
or before February 28, 2012.

 

	 	Very truly yours,
	 	 
	Dated:  February 8, 2012	 
	 	Signature
	 	 
	 	 
	 	Printed Name and Title (if applicable)
	 	 
	 	 
	 	Address

 

    	-2-

    	 

    

 

	Page 3

 

Exhibit A

 

Securities of Cytomedix, Inc. 

 

    	-3-VOTING AGREEMENT

 

This
VOTING AGREEMENT (this “Agreement”) is dated as of February 8, 2012, by and between the undersigned holder (the
“Holder”) of Common Stock of Cytomedix, Inc., a Delaware corporation (“Cytomedix” or the “Company”),
and Cytomedix. All capitalized terms used but not defined herein shall have the meanings assigned to them in the Exchange Agreement
(as defined below).

 

WHEREAS, concurrently
with the execution of this Agreement, the Holder and the Company are entering into a Subscription Agreement for the purchase of
shares of Cytomedix Common Stock (the "Subscription Agreement") as contemplated under that certain Exchange and Purchase
Agreement (as such agreement may be subsequently amended or modified, the "Exchange Agreement"); and

 

WHEREAS, upon the
consummation of the Holder's purchase of the Cytomedix Common Stock pursuant to the Subscription Agreement, the Holder will beneficially
own and have sole or shared voting power with respect to the number of shares of the Company's Common Stock identified on Exhibit
A hereto (such shares, together with all shares of the Company's common stock subsequently acquired by the Holder during the term
of this Agreement, including through the exercise of any stock option or other equity award, warrant or similar instrument, being
referred to as the "Shares").

 

NOW,
THEREFORE, in consideration of the premises and the mutual covenants contained herein and, and other good and valuable consideration,
receipt and sufficiency is hereby acknowledged by the parties hereto, the parties hereto agree as follows:

 

Section 1.  
Agreement to Vote Shares.  The Holder agrees that, while this Agreement is in effect, at any meeting of stockholders
of the Company, however called, or at any adjournment thereof (the “Meeting”), or in any other circumstances in which
the Holder is entitled to vote, consent or give any other approval, except as otherwise agreed to in writing in advance by the
Company, the Holder shall: (i) appear at each such meeting or otherwise cause the Shares to be counted as present thereat for purposes
of calculating a quorum; and (ii) vote (or cause to be voted), in person or by proxy, all the Shares that are beneficially
owned by the Holder or as to which the Holder has, directly or indirectly, the right to vote or direct the voting, in favor of
proposals to:

 

		(1)	approve an amendment to Article Four of the Company’s Certificate of Incorporation, as amended
to date, to increase the authorized shares of common stock from 100,000,000 to 160,000,000 shares;

 

		(2)	authorize the Board of Directors to effect, in its discretion prior to December 31, 2012, a reverse
stock split of the outstanding shares of the Company’s common stock in a ratio of at least [1-for-3] and of up to a maximum
of 1-for-5, to be determined within such range in the sole discretion of the Board of Directors, to facilitate the Company’s
listing application on a national securities exchange; and

 

		(3)	ratify the increase in shares available for issuance under the Company’s Long-Term Incentive
Option Plan from 8,000,000 to 10,500,000 as approved by the Company’s board of directors on February 2, 2012.

 

 

    	 

    	 

    

 

Section 2.  
Representations and Warranties of Holder. The Holder represents and warrants to the Company as follows: 

 

 

(a)      the
Holder has all requisite capacity and authority to enter into and perform its/his obligations under this Agreement.

 

(b)      This
Agreement has been duly executed and delivered by the Holder and constitutes the valid and legally binding obligation of the Holder
enforceable against the Holder in accordance with its terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization,
moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles.

 

(c)      The
execution and delivery of this Agreement by the Holder does not, and the performance by the Holder of its obligations hereunder
and the consummation by the Holder of the transactions contemplated hereby will not, violate or conflict with, or constitute a
default under, any agreement, instrument, contract or other obligation or any order, arbitration award, judgment or decree to which
the Holder is a party or by which the Holder is bound, or, to the Holder’s knowledge, any statute, rule or regulation to
which the Holder is subject or, in the event that the Holder holds any of the Shares indirectly through a corporation, partnership,
trust or other entity, any charter, bylaw or other organizational document of such entity; in each case, such that the Holder would
not be able to fulfill his or her obligations pursuant to this Agreement.

 

(d)      The
Holder is the record or beneficial owner of, or is the trustee that is the record holder of, and whose beneficiaries are the beneficial
owners of, and has good title to all of the Shares and options set forth on Exhibit A hereto, and the Shares and options
are so owned free and clear of any liens, security interests, charges or other encumbrances that relate to or would affect the
authority or power of the Holder to vote the Shares as contemplated herein, except as otherwise described on Exhibit A
hereto. The Holder does not own, of record or beneficially, any shares of capital stock of the Company other than the Shares. The
Shares do not include shares over which the Holder exercises control in a fiduciary capacity and no representation by the Holder
is made thereby pursuant to the terms hereof. The Holder has the right to vote the Shares, and none of the Shares is subject to
any voting trust or other agreement, arrangement or restriction with respect to the voting of the Shares, except as contemplated
by this Agreement.

 

Section 3.  
Specific Performance; Remedies; Attorney Fees.   The Holder acknowledges that it will be impossible to
measure in money the damage to the Company if the Holder fails to comply with the obligations imposed by this Agreement and that,
in the event of any such failure, the Company will not have an adequate remedy at law or in equity. Accordingly, the Holder agrees
that injunctive relief or other equitable remedy is the appropriate remedy for any such failure and will not oppose the granting
of such relief on the basis that the Company has an adequate remedy at law. The Holder further agrees that the Holder will not
seek, and agrees to waive any requirement for, the securing or posting of a bond in connection with the Company’s seeking
or obtaining such equitable relief. In addition, after providing written notification to the Holder, the Company shall have the
right to inform any third party that the Company reasonably believes to be, or to be participating with the Holder or receiving
from the Holder assistance in violation of this Agreement, of the terms of this Agreement and of the rights of the Company hereunder,
and that participation by any such persons with the Holder in activities in violation of this Agreement may give rise to claims
by the Company against such third party.

 

    	-2-

    	 

    

 

Section 4.  
Term of Agreement; Termination.   Except as otherwise provided in this Section 4, the term of this Agreement
shall commence on the date hereof and shall expire upon the date of the Company’s Current Report on Form 8-K is filed with
the Securities and Exchange Commission disclosing the results of the Meeting, but in no event later than June 30, 2012 (the “Announcement”).
This Agreement may be terminated at any time prior to the Announcement by the written consent of the parties hereto, and shall
be automatically terminated in the event that the Conversion Agreement is terminated in accordance with its terms. Upon termination,
no party shall have any further obligations or liabilities hereunder; provided, however, such termination shall not relieve any
party from liability for any willful breach of this Agreement prior to such termination.

 

Section 5.  
Company and Transfer Agent.   The Company is hereby authorized to disclose the existence of this Agreement
to its transfer agent.

 

Section 6.  
Entire Agreement; Amendments.   This Agreement supersedes all prior agreements, written or oral, among
the parties hereto with respect to the subject matter hereof and contains the entire agreement among the parties with respect to
the subject matter hereof. This Agreement may not be amended, supplemented or modified, and no provisions hereof may be modified
or waived, except by an instrument in writing signed by each party hereto. No waiver of any provisions hereof by either party shall
be deemed a waiver of any other provision hereof by any such party, nor shall any such waiver be deemed a continuing waiver of
any provision hereof by such party.

 

Section 7.  
Severability.   In the event that any one or more provisions of this Agreement shall for any reason be
held invalid, illegal or unenforceable in any respect, by any court of competent jurisdiction, such invalidity, illegality or unenforceability
shall not affect any other provisions of this Agreement and the parties shall use their reasonable efforts to substitute a valid,
legal and enforceable provision which, insofar as practical, implements the purposes and intents of this Agreement.

 

Section 8.  
Capacity as Stockholder.  The obligations of Holder under this Agreement are several and not joint with the
obligations of any other person or entity. Nothing contained herein, and no action taken by Holder pursuant hereto, shall be deemed
to constitute Holder as a partnership, syndicate or other group (in each case, within the meaning of Section 13(d)(3) of the Securities
Exchange Act of 1934, as amended) with any other person or entity, or create a presumption that Holder is in any way acting in
concert or as a group with any other person or entity with respect to such obligations or the transactions contemplated by this
Agreement or any other matters, and the Company acknowledges that Holder is not acting in concert or as a group with any other
person or entity, and the Company shall not assert any such claim, with respect to such obligations or the transactions contemplated
by this Agreement. The decision of Holder to enter into this Agreement has been made by Holder independently of any other person
or entity. The Company confirms that Holder has independently participated with the Company in the negotiation of the transaction
contemplated hereby with the advice of its own counsel and advisors. It is expressly understood and agreed that each provision
contained in this Agreement is between the Company and Holder, solely, and not (i) between the Company, on the one hand, and Holder
and any other person or entity, on the other hand, or (ii) between or among Holder and any other person or entity.

 

Section 9.  
Governing Law.   This Agreement shall be governed by, and interpreted in accordance with, the laws of the
State of Delaware, without regard for conflict of law provisions.

 

[Remainder of page
intentionally left blank]

 

    	-3-

    	 

    

 

IN
WITNESS WHEREOF, the parties hereto have executed and delivered this Agreement as of the date first written above.

 

	 	CYTOMEDIX, INC.
	 	 
	 	By:	 
	 	 	Name: Martin P. Rosendale
	 	 	Title: Chief Executive Officer

 

 

	 	HOLDER:
	 	 
	 	
	 	 	 
	 	By:	 
	 	 	Name:
	 	 	Title:

 

    	-4-

    	 

    

 

EXHIBIT A

 

	Holder	Shares of Common Stock

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00199-of-00352.parquet"}]]